# Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

> **NCT06438627** · PHASE3 · RECRUITING · sponsor: **XIANG YANQUN** · enrollment: 164 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** TPC combined with Apatinib and Camrelizumab
- **DRUG:** GP Combined With Camrelizumab

## Key facts

- **NCT ID:** NCT06438627
- **Lead sponsor:** XIANG YANQUN
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438627, "Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06438627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*